{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"242"}],"units":"Participants"}],"description":"For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed at least one positive post-baseline ADA result during the randomized phase, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result.","groups":[{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG000","title":"Atezolizumab"},{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion and lurbinectedin, 3.2 mg/m\\^2, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG001","title":"Atezolizumab+ Lurbinectedin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ADA-evaluable population was defined as participants with at least one post-dose evaluable ADA sample (collected in the randomized phase).","reportingStatus":"POSTED","timeFrame":"Up to 26 months","title":"Randomized Phase: Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab","type":"SECONDARY","unitOfMeasure":"Participants"}